Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: Waiting for godot?

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 6, 2008, Pages 815-818

  Brilakis, Emmanouil S ^a   Berger, Peter B ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

Coronary artery bypass graft surgery; Percutaneous coronary intervention; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN; METAL;

BARE METAL STENT; DRUG ELUTING STENT; EDITORIAL; GRAFT DYSFUNCTION; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; SURGICAL MORTALITY; TREATMENT RESPONSE; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; GRAFT OCCLUSION; INSTRUMENTATION; NOTE; PRACTICE GUIDELINE; RISK ASSESSMENT; SAPHENOUS VEIN; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; GRAFT OCCLUSION, VASCULAR; HUMANS; METALS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SAPHENOUS VEIN; STENTS; TREATMENT OUTCOME;

EID: 58849094598     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21657     Document Type: Editorial

References (19)

1. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-747.
2. Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: A prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998;32:1861-1865.
3. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: Proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50:1442-1449.
4. Hanekamp CE, Koolen JJ, Den Heijer P, et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: The Venestent study. Cathet Cardiovasc Interv 2003;60:452-457.
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
6. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48:2423-2431.
7. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized delayed RRISC Trial. J Am Coll Cardiol 2007;50:261-267.
8. Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007;28:719-725.
9. Applegate R, Sacrinty M, Kutcher M, Santos R, Gandhi S, Little W. Late outcomes of drug-eluting versus bare metal stents in SVGs: Propensity score analysis. Cathet Cardiovasc Interv, in press.
10. Mehta RH, Honeycutt E, Peterson ED, et al. Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. Circulation 2006;114 (1 Suppl):I396-I401.
11. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-994.
12. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Cathet Cardiovasc Interv 2005;66:507-511.
13. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: Clinical and angiographic follow-up results from a multicentre study. Heart 2007;93:331-334.
14. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007;20:458-465.
15. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
16. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cyphertrade mark stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: Results of a multicenter 350-patient case-control study. J Invas Cardiol 2007;19:404-409.
17. Wohrle J, Nusser T, Kestler HA, Kochs M, Hombach V. Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-express stent with the bare-metal express stent for saphenous vein graft interventions. Clin Res Cardiol 2007;96:70-76.
18. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Cathet Cardiovasc Interv 2008;71:58-61.
19. Berger PB. Can euphoria be bad? J Am Coll Cardiol 2003;41: 1289-1292.